Myriad Presents Initial Phase IIa Data for Metastatic Melanoma Agent

Myriad Pharmaceuticals, Inc. … announced the presentation of initial clinical data from an ongoing Phase 2a study of Azixa, a microtubule destabilizing agent in stage 4 melanoma patients.
StreetInsider